Artivion (AORT) just wrapped up FY 2025 with Q4 revenue of US$116.0 million and basic EPS of US$0.05, alongside net income of US$2.4 million. The company has seen revenue move from US$97.3 million and a basic EPS loss of US$0.39 in Q4 FY 2024 to US$116.0 million and US$0.05 in Q4 FY 2025. Trailing twelve month figures now sit at US$441.3 million of revenue and basic EPS of US$0.22 with net income of US$9.8 million, pointing to a business that is now covering its costs and starting to build out more stable margins.

See our full analysis for Artivion.

With the latest numbers on the table, the next step is to see how this shift in profitability and revenue scale lines up with the key narratives investors have been following around Artivion.

Trailing 12-Month Profit Hits US$9.8 Million

• Over the last 12 months, Artivion moved from a trailing net loss to trailing net income of US$9.8 million with basic EPS of US$0.22, compared with trailing figures of a net loss of US$13.3 million and basic EPS of US$0.32 loss at FY 2024 Q4.
• Consensus narrative points to new products and market expansion as key supports for this shift, and the numbers give some backing:
  • Quarterly net income moved from a loss of US$16.5 million in FY 2024 Q4 to a profit of US$2.4 million in FY 2025 Q4, alongside revenue rising from US$97.3 million to US$116.0 million over the same quarters.
  • Analysts also expect earnings growth of about 32.6% per year alongside revenue growth of roughly 10.7% per year. This fits a story where higher margins, not just sales volume, are an important driver.

Analysts watching this move into profitability are asking whether the margin story can last as product launches mature and growth normalizes, which is exactly what the broader narrative tries to unpack. 📊 Read the what the Community is saying about Artivion.

EPS Trend Shows Bumpier Path Inside FY 2025

• Within FY 2025, basic EPS moved from a loss of US$0.01 in Q1 to a high of US$0.14 in Q3, then eased back to US$0.05 in Q4, while quarterly net income ranged from a loss of US$0.5 million in Q1 to a profit of US$6.5 million in Q3 and US$2.4 million in Q4.
• For bullish investors, this pattern still leans positive, but the quarterly swings matter against the growth story:
  • Consensus narrative highlights operational efficiency and new product launches as helping profitability, and the move from a trailing net loss of US$21.4 million at FY 2025 Q1 to trailing net income of US$9.8 million by FY 2025 Q4 is consistent with that view.
  • At the same time, the step down in quarterly EPS from US$0.14 in Q3 to US$0.05 in Q4 shows that profit progress has not been in a straight line. Readers may want to factor this in when thinking about how smooth that earnings path might be.

P/S of 3.9x With DCF Fair Value Above Market

• The stock trades on a trailing P/S of 3.9x, compared with a peer average of 4.4x and a US Medical Equipment industry average of 2.8x, while the DCF fair value of US$62.92 and an analyst price target of US$50.75 both sit above the current share price of US$35.42.
• Consensus narrative treats new products and regulatory approvals as drivers of this gap between trading price and valuation references, and the current numbers frame that tension clearly:
  • On one side, the company is described as having high quality past earnings with trailing revenue of US$441.3 million and trailing EPS of US$0.22, which helps explain why DCF fair value and the analyst target are above the market price.
  • On the other, the stock sits at a richer P/S multiple than the broader industry, so anyone using that 3.9x figure has to weigh the recent move to profitability and growth forecasts against paying more per dollar of sales than the average medical equipment peer.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Artivion on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of optimism and concern running through this update, it makes sense to look at the underlying data yourself and decide how comfortable you are with the balance of potential upside and downside. To help frame that assessment, take a moment to review the 4 key rewards and 1 important warning sign

See What Else Is Out There

Artivion's recent move into profitability comes with uneven quarterly EPS and a P/S of 3.9x, which may leave some investors cautious about valuation and consistency.

If that mix of choppy earnings and a richer sales multiple makes you hesitate, broaden your watchlist with 72 resilient stocks with low risk scores that aim for steadier profiles and reduced downside risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.